Lexicon Pharmaceutcl (LXRX)

Jan 2, 2025, 8:00 AM EST - 16 days ago

Lexicon Appoints Scott Coiante as Chief Financial Officer

Dec 20, 2024, 4:46 PM EST - 4 weeks ago

US FDA declines to approve Lexicon Pharma's add-on diabetes drug

Dec 20, 2024, 4:30 PM EST - 4 weeks ago

Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)

Nov 26, 2024, 8:00 AM EST - 7 weeks ago

Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

Nov 25, 2024, 4:15 PM EST - 7 weeks ago

Lexicon Pharmaceuticals to Participate in December Investor Conferences

Nov 22, 2024, 7:47 AM EST - 2 months ago

Lexicon Pharmaceuticals to cut workforce by 60% to focus on drug development

Nov 22, 2024, 7:32 AM EST - 2 months ago

Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA

Nov 20, 2024, 4:05 PM EST - 2 months ago

Lexicon Appoints Ivan H. Cheung to Board of Directors

Nov 12, 2024, 8:39 PM EST - 2 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 2 months ago

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 6, 2024, 8:00 AM EST - 2 months ago

Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference

Nov 5, 2024, 4:05 PM EST - 2 months ago

Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease

Oct 31, 2024, 6:54 PM EDT - 2 months ago

Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

Oct 31, 2024, 4:54 PM EDT - 2 months ago

FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes

Oct 16, 2024, 4:35 PM EDT - 3 months ago

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe

Oct 16, 2024, 4:34 PM EDT - 3 months ago

Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe

VTRS

Sep 27, 2024, 8:00 AM EDT - 4 months ago

Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress

Sep 16, 2024, 8:00 AM EDT - 4 months ago

Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer

Sep 10, 2024, 8:00 AM EDT - 4 months ago

New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes

Sep 3, 2024, 4:00 PM EDT - 4 months ago

Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences

Aug 13, 2024, 8:30 AM EDT - 5 months ago

Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio

Aug 7, 2024, 8:00 AM EDT - 5 months ago

Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists

Aug 3, 2024, 6:29 AM EDT - 6 months ago

Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success

Aug 1, 2024, 11:00 PM EDT - 6 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2024 Earnings Call Transcript

Jul 25, 2024, 8:00 AM EDT - 6 months ago

Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024

Jul 8, 2024, 9:15 AM EDT - 6 months ago

Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director

Jun 21, 2024, 8:00 AM EDT - 7 months ago

Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes

Jun 19, 2024, 8:00 AM EDT - 7 months ago

Data From Lexicon's RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

Jun 14, 2024, 8:00 AM EDT - 7 months ago

Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association

May 29, 2024, 8:00 AM EDT - 8 months ago

Lexicon Pharmaceuticals Selects Medidata to Help Advance First Non-Opioid Drug for Neuropathic Pain in Over Two Decades

May 29, 2024, 7:30 AM EDT - 8 months ago

Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024

May 14, 2024, 7:00 AM EDT - 8 months ago

New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction

May 9, 2024, 7:30 AM EDT - 9 months ago

Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024

May 5, 2024, 5:14 AM EDT - 9 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2024 Earnings Call Transcript

May 2, 2024, 4:05 PM EDT - 9 months ago

Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 29, 2024, 9:00 AM EDT - 9 months ago

Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals

Apr 18, 2024, 8:00 AM EDT - 9 months ago

Lexicon Pharmaceuticals to Host 2024 Investor Day

Mar 25, 2024, 9:20 AM EDT - 10 months ago

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo

Mar 11, 2024, 7:15 AM EDT - 11 months ago

Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update

Mar 11, 2024, 7:05 AM EDT - 11 months ago

Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities

Jan 26, 2024, 10:31 AM EST - 1 year ago

Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do

Jan 4, 2024, 1:03 PM EST - 1 year ago

Lexicon Pharma: Inpefa's Early Clinical Benefits, Rehospitalization Data May Unlock Significant Value

Dec 21, 2023, 4:15 PM EST - 1 year ago

Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference

Nov 30, 2023, 7:30 AM EST - 1 year ago

Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

Nov 22, 2023, 7:30 AM EST - 1 year ago

Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference

Nov 12, 2023, 2:10 PM EST - 1 year ago

INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data

Nov 10, 2023, 4:01 PM EST - 1 year ago

Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

Nov 8, 2023, 11:01 AM EST - 1 year ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 7:00 AM EST - 1 year ago

Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 3, 2023, 9:00 AM EDT - 1 year ago

Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023